Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: a pilot study.
BACKGROUND
The combination of intravenous iron and recombinant human erythropoietin has been proved to be effective in the treatment of refractory anaemia in patients with inflammatory bowel disease (IBD). Darbepoetin-alpha (DPO) has a three-fold longer terminal half-life than erythropoietin. The purpose of this pilot study was to determine whether darbepoetin-alpha is also effective for the treatment of refractory anaemia in IBD.


METHODS
Twenty IBD patients (nine ulcerative colitis and 11 Crohn's disease) and refractory anaemia received intravenous iron sucrose (total iron dose 1.3+/-0.5 g, range 0.7-1.9) and darbepoetin-alfa at the single, weekly dose of 0.9 microg/kg subcutaneously for 4 weeks. Serum erythropoietin, ferritin, transferrin, soluble transferrin receptor, C-reactive protein and interleukin-6 were measured at baseline and after treatment.


RESULTS
Haematopoietic response (increase of haemoglobin > or = 2.0 g/dl) was observed in 15 out of the 20 patients (75%). The mean haemoglobin concentrations increased from 9.48+/-0.82 g/dl at baseline to 12.71+/-1.12 g/dl after treatment (P<0.0001). Mean corpuscular volume and serum ferritin levels were also significantly increased whereas mean C-reactive protein levels and endogenous erythropoietin levels significantly decreased after treatment.


CONCLUSIONS
In IBD patients with refractory anaemia the administration of darbepoetin in combination with intravenous iron sucrose can raise haemoglobin levels.
Koutroubakis
Ioannis E
IE
Department of Gastroenterology, University Hospital Heraklion, Crete, Greece. ktjohn@her.forthnet.gr
Karmiris
Konstantinos
K
Makreas
Sokratis
S
Xidakis
Costas
C
Niniraki
Maria
M
Kouroumalis
Elias A
EA
D000753:Anemia, Refractory / Q000188:drug therapy* / Q000209:etiology; D002097:C-Reactive Protein / Q000032:analysis; D000068256:Darbepoetin alfa; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D005260:Female; D005290:Ferric Compounds / Q000627:therapeutic use*; D000077605:Ferric Oxide, Saccharated; D005293:Ferritins / Q000097:blood; D005937:Glucaric Acid; D006397:Hematinics / Q000627:therapeutic use*; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000150:complications*; D007275:Injections, Intravenous; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D010865:Pilot Projects; D011990:Receptors, Transferrin / Q000097:blood; D014168:Transferrin / Q000032:analysis; D016896:Treatment Outcome
D005290:Ferric Compounds; D006397:Hematinics; D006454:Hemoglobins; D015850:Interleukin-6; D011990:Receptors, Transferrin; D014168:Transferrin; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D002097:C-Reactive Protein; D005293:Ferritins; D000077605:Ferric Oxide, Saccharated; D005937:Glucaric Acid